Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Web Exclusives
Ovarian Cancer
Increased Uptake of Neoadjuvant Chemotherapy Does Not Explain Trend Toward Improved Survival in Advanced Ovarian Cancer
Read More
Ovarian Cancer
Platinum-Based Chemotherapy Following Progression on PARP Inhibitor Maintenance Yields Greatest Benefit in Advanced Ovarian Cancer with Platinum-Free Interval >12 Months
Read More
FDA Oncology Update
Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions
Read More
Meeting Highlights
ESMO Highlights
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Read More
Ovarian Cancer
ASCO Guidelines Support PARP Inhibitor Use in Maintenance and Recurrent Setting of Advanced Ovarian Cancer
Read More
Ovarian Cancer
Niraparib Efficacy in Advanced Ovarian Cancer Extends to All Biomarker Subgroups
Read More
Ovarian Cancer
Olaparib/Bevacizumab as First-Line Maintenance Reduces Risk for Progression or Death in Patients with Advanced Ovarian Cancer
Read More
Ovarian Cancer
Online Delivery of Genetic Services: No Increase in Cancer Risk Distress versus Telephone Counseling
Read More
Lung Cancer
Rearrangement During Transfection (RET) Fusions and Their Role as Oncogenic Drivers
Read More
Lung Cancer
Molecular Profiling Is Critical for Optimizing NSCLC Therapy
Read More
6
7
8
9
10
11
12
Page 9 of 42
Results 81 - 90 of 417